ABVC BIOPHARMA, INC.

ABVC BioPharma has reported zero cyber incidents and zero red-flag 8-K filings (bankruptcy, delisting, restatement, or officer departures) over the past 90 days. This absence of acute distress signals provides a baseline stability snapshot, though a 90-day window captures only recent activity. The full $49 Report extends analysis to 12 months of filing history, adds a dilution risk quantification, maps financing runway and equity issuance patterns, and screens for AI-driven anomalies in disclosure language and SEC filing metadata. The full $49 Report adds comprehensive dilution scoring, 12-month event context, and AI risk signal detection across all SEC filings and press releases.